Protagonist Therapeutics, Inc (PTGX) company profile
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
About Protagonist Therapeutics
Pharmaceutical Preparations, SIC 2834
Protagonist Therapeutics is an integrated biopharmaceutical company focused on discovering and developing differentiated peptide-based medicines. The company organizes its research across three core therapeutic segments: inflammation and immunology, hematology, and metabolic diseases. Key development-stage assets include icotrokinra for plaque psoriasis, rusfertide for polycythemia vera, and preclinical candidates targeting obesity and related conditions. Operating primarily through strategic partnerships, Protagonist collaborates with major multinational pharmaceutical corporations such as Janssen Biotech and Takeda Pharmaceuticals for Phase 2 and Phase 3 development, regulatory submissions, and commercialization.
The company engages in clinical development and regulatory activities spanning the United States and Europe, supported by worldwide licensing and collaboration structures. Its late-stage candidates have been submitted for regulatory review to both the U.S. Food and Drug Administration and the European Medicines Agency. The provided text does not state the company's headquarters location or the physical count of its operating facilities.
Summary of the business section of Protagonist Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Protagonist Therapeutics, Inc
- Headquarters
- Newark, CA
- Address
- 7707 Gateway Blvd., Suite 140 94560-1160
- Phone
- (510) 474-0170
- Website
- protagonist-inc.com
- Employees
- 132, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California, USA
Stock & identifiers
- Ticker
- PTGX
- Exchange
- Nasdaq
- IPO date
- Aug 12, 2016
- Shares outstanding
- 65M, Jul 31, 2026
- Public float
- $2.90B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1377121
- CUSIP
- 74366E102
- ISIN
- US74366E1029
- FIGI
- BBG002B63KM7
- Share class FIGI
- BBG002B63KP4
- EIN
- 98-0505495
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dinesh V. Ph D. Patel | President and CEO, Director | 522,968 |
| Arturo Molina Md | Chief Medical Officer | 81,397 |
| Asif Ali | Chief Financial Officer | 59,003 |
| Suneel Gupta | Chief Development Officer | 267,433 |
| William D. Waddill | Director | 7,825 |
| Bryan Giraudo | Director | 12,695 |
| Harold E. Selick | Director | 84,845 |
| Lewis T. Williams | Director | 7,825 |
| Sarah A. O'Dowd | Director | 7,825 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $12.87M | $46.07M | $3.68M | $433 | $125 |
| FY2024 | $9.47M | $17.93M | $3.00M | $191 | $93 |
| FY2023 | $7.07M | $15.33M | $1.81M | $114 | $94 |
| FY2022 | $5.99M | -$5.17M | $2.47M | $54 | $90 |
| FY2021 | $5.54M | $12.11M | $2.22M | $170 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Dinesh V. Patel, Ph.D. President and Chief Executive Officer | $715.50K | $5.84M | $5.62M | $686.88K | $11.91K | $12.87M | +36% |
| Asif Ali EVP, Chief Financial Officer | $500.00K | $1.24M | $1.19M | $320.00K | $6.24K | $3.26M | +16% |
| Arturo Molina, M.D., M.S., F.A.C.P. Chief Medical Officer | $572.00K | $1.60M | $1.54M | $366.08K | $11.91K | $4.10M | +18% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 12, 2016
- Offer price
- $12.00
- Securities offered
- 7,500,000
- Gross proceeds
- $90.00M
- Exchange
- Nasdaq
- First trading day
- Aug 11, 2016
- First-day close
- $11.70-2.5%
- Lock-up ends (est.)
- Feb 7, 2017
“The initial public offering price is $12.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, our total global workforce consisted of 132 full-time equivalent employees, 103 of whom were in research and development.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 3, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 18, 2020 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 12, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 5, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 28, 2006 | Name change | Name changed from Protagonist Inc to Protagonist Therapeutics Inc |
See a number that looks wrong?